BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19210223)

  • 1. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
    Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
    Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
    J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response for L1, E6 and E7 HPV 16 and HPV 18 antigens in Tunisian women with cervical cancer and controls.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maalej M; Oueslati R
    J Immunoassay Immunochem; 2008; 29(3):266-80. PubMed ID: 18569375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological study in Tunisian cervical cancer patients.
    Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R
    Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
    Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
    Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
    Layman H; Rickert KW; Wilson S; Aksyuk AA; Dunty JM; Natrakul D; Swaminathan N; DelNagro CJ
    PLoS One; 2020; 15(3):e0229672. PubMed ID: 32214362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
    Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
    Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
    de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
    Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations of human papillomavirus type 58 E6, E7, L1 genes and long control region in strains from women with cervical lesions in Liaoning province, China.
    Liu JH; Lu ZT; Wang GL; Zhou WQ; Liu C; Yang LX; Sun ZR; Ruan Q
    Infect Genet Evol; 2012 Oct; 12(7):1466-72. PubMed ID: 22659102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of HPV infection and survival in patients with head and neck tumors.
    Koslabova E; Hamsikova E; Salakova M; Klozar J; Foltynova E; Salkova E; Rotnaglova E; Ludvikova V; Tachezy R
    Int J Cancer; 2013 Oct; 133(8):1832-9. PubMed ID: 23564321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.
    Combes JD; Pawlita M; Waterboer T; Hammouda D; Rajkumar T; Vanhems P; Snijders P; Herrero R; Franceschi S; Clifford G
    Int J Cancer; 2014 Nov; 135(10):2453-61. PubMed ID: 24729277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies.
    Endo F; Tabata T; Sadato D; Kawamura M; Ando N; Oboki K; Ukaji M; Kobayashi K; Kobayashi Y; Ikeda T; Shibasaki F
    PLoS One; 2017; 12(2):e0171314. PubMed ID: 28158224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.
    Phaëton R; Gutierrez J; Jiang Z; Karabakhtsian RG; Albanese J; Sunkara J; Fisher DR; Goldberg GL; Dadachova E
    Immunotherapy; 2015; 7(6):631-40. PubMed ID: 26098137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and serologic markers of HPV 16 infection are associated with local recurrence in patients with oral cavity squamous cell carcinoma.
    Huang CG; Lee LA; Liao CT; Yen TC; Yang SL; Liu YC; Li JC; Gong YN; Kang CJ; Huang SF; Fang KH; Chang KP; Lee LY; Hsueh C; Shih SR; Tsao KC
    Oncotarget; 2017 May; 8(21):34820-34835. PubMed ID: 28422732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.